Swiss National Bank
TPST icon

Swiss National Bank’s Tempest Therapeutics TPST Stock Holding History

Swiss National Bank’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15
Closed -$83K – 2569
2017
Q1 		$83K Hold
15
– – ﹤0.01% 2532
2016
Q4 		$68K Hold
15
– – ﹤0.01% 2564
2016
Q3 		$319K Hold
15
– – ﹤0.01% 2469
2016
Q2 		$232K Buy
15
+3
+25% +$68.5K ﹤0.01% 2549
2016
Q1 		$316K Buy
12
+3
+33% +$63.4K ﹤0.01% 2476
2015
Q4 		$269K Hold
9
– – ﹤0.01% 2520
2015
Q3 		$233K Buy
9
+1
+13% +$67.3K ﹤0.01% 2461
2015
Q2 		$680K Buy
+8
New +$733K ﹤0.01% 2045

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Swiss National Bank's TPST Position: Q2 2017 in Review

Swiss National Bank sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 15 shares — an estimated $83K sold.

Swiss National Bank first reported a position in TPST in Q2 2015 and held it in 8 quarters. The position peaked at $680K in Q2 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

  • Swiss National Bank reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Swiss National Bank sold 15 Tempest Therapeutics shares in Q2 2017, an estimated $83K.
  • Swiss National Bank first reported a position in Tempest Therapeutics in Q2 2015 and held it in 8 quarters.
  • Swiss National Bank's Tempest Therapeutics position peaked at $680K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Swiss National Bank's 13F filing for Q2 2017, filed 9 Aug 2017.